2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119810
    Seletracetam 357336-74-4 99.88%
    Seletracetam (Ucb 44212), as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy.
    Seletracetam
  • HY-121118
    Coronaridine 467-77-6 99.72%
    Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression.
    Coronaridine
  • HY-121392
    GR 125743 148547-33-5 99.77%
    GR 125743 is a selective 5-HT1B/1D receptor antagonist, with pKis of 8.85 and 8.31 for wild-type h5-HT1B and wild-type h5-HT1D, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases.
    GR 125743
  • HY-121537
    CAY10404 340267-36-9 ≥99.0%
    CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities.
    CAY10404
  • HY-121653
    Flesinoxan 98206-10-1 99.90%
    Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects.
    Flesinoxan
  • HY-121872
    DP-b99 222315-88-0
    DP-b99 is a chelator of zinc and calcium ions that acts selectively within cell membranes and has neuroprotective properties in animal models of stroke.
    DP-b99
  • HY-122672
    Adhesamine 462605-73-8 98.04%
    Adhesamine, dumbbell-shaped molecule, activates MAPK/FAK pathway. Adhesamine promotes adhesion and growth of mammalian cells. Adhesamine accelerates the differentiation and improves the survival of mice hippocampal neurons in primary culture.
    Adhesamine
  • HY-123495
    CRANAD-28 1623747-97-6 98.03%
    CRANAD-28 is a robust fluorescent compound for visualization of amyloid beta plaques.
    CRANAD-28
  • HY-124424
    VU0071063 333415-38-6 99.71%
    VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC50=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships.
    VU0071063
  • HY-124543
    MRS-1191 185222-90-6 99.22%
    MRS-1191 is a potent and selective A3 adenosine receptor antagonist with a KB value of 92 nM, a Ki value of 31.4 nM for human A3 receptor and an IC50 of 120 nM for CHO cells. MRS-1191 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRS-1191
  • HY-124591
    TC-2153 1381769-23-8 98.73%
    TC-2153 is a selective inhibitor of striatal-enriched protein tyrosine phosphatase (STEP), with psychotropic activity and low acute toxicity. TC-2153 increases the expression of brain-derived neurotropic factor (BDNF) in the brain. And it decreases MAOA and 5-HT1A receptors mRNA level in midbrain. TC-2153 also inhibits 5-HT2A receptor-mediated signaling.
    TC-2153
  • HY-124673
    AF40431 181125-92-8 98.09%
    AF40431, the first reported small-molecule ligand of sortilin, has an IC50 of 4.4 µM and a Kd of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.
    AF40431
  • HY-125967
    AM 374 86855-26-7
    AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC50 value of 13 nM. AM 374 can be used for the research of neurological disease.
    AM 374
  • HY-126066
    (-)-Syringaresinol 6216-81-5 99.95%
    (-)-Syringaresinol is an orally active isomer of syringaresinol (HY-N8307) found in Annona Montana. (-)-Syringaresinol exhibits antioxidant, anti-inflammatory, and anticancer activities. (-)-Syringaresinol can alleviate ulcerative colitis via the PI3K-Akt/MAPK/Wnt signaling pathway. (-)-Syringaresinol inhibits HL-60 cell proliferation by arresting the G1 phase and inducing apoptosis. (-)-Syringaresinol inhibits LPS (HY-D1056)-induced microglial activation by downregulating the NF-κB p65 signaling pathway and its interaction with ERβ, exerting anti-neuroinflammatory effects.
    (-)-Syringaresinol
  • HY-12766S
    Bupropion morpholinol-d6 1216893-18-3 99.28%
    Bupropion morpholinol-d6 is the deuterated form of Bupropion morpholinol. Bupropion morpholinol is a major metabolite of Bupropion. Bupropion morpholinol inhibits Dopamine, Norepinephrine transporters and the α4β2 nicotinic receptor in vitro. Bupropion morpholinol contributes to antidepressant and smoking cessation activities.
    Bupropion morpholinol-d6
  • HY-128733
    Phenyl acetate 122-79-2 99.68%
    Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression.
    Phenyl acetate
  • HY-128975
    m-Tyramine hydrobromide 38449-59-1 98.50%
    m-Tyramine hydrobromide is an endogenous trace amine neuromodulator. m-Tyramine hydrobromide has effects on the adrenergic and dopaminergic receptor[1, 2].
    m-Tyramine hydrobromide
  • HY-129674
    PHA 568487 free base 527680-56-4 99.29%
    PHA 568487 free base is a selective alpha 7 nicotinic acetylcholine receptor (α-7 nAchR) agonist. PHA 568487 free base reduces neuroinflammation.
    PHA 568487 free base
  • HY-130553
    β-Spaglumic acid 4910-46-7 99.97%
    β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (Ki=1 µM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus). β-Spaglumic acid can be used in neuroprotection-related studies.
    β-Spaglumic acid
  • HY-133111
    3-Hydroxy agomelatine 166526-99-4 99.13%
    3-Hydroxy agomelatine is a metabolite of Agomelatine. 3-Hydroxy agomelatine is a 5-HT2C receptor antagonist with an IC50 of 3.2 μM and a Ki of 1.8 μM.
    3-Hydroxy agomelatine
Cat. No. Product Name / Synonyms Application Reactivity